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Neisseria  meningitidis  group  B (MenB)  is  a leading  cause  of meningitis  and  sepsis.  A  new  vaccine  has
been  recently  licensed.  The  aim  of  the  present  study  was to  evaluate  the  epidemiology  of MenB  disease
in  pediatric  age  and  deﬁne  the  optimal  age for vaccination.  All  patients  aged 0–18 years  admitted  with
a  diagnosis  of  meningitis  or  sepsis  to  the  83  participating  Italian  pediatric  hospitals  were included  in
the  study.  Blood  and/or  cerebrospinal  ﬂuid  (CSF)  samples  were  tested  by  Realtime-PCR  and/or  culture.
One hundred  and  thirty-six  cases  (mean  age  5.0  years,  median  2.7)  of MenB  disease  were  found.  Among
these,  96/136  (70.6%)  were  between  0 and  5  years,  61/136  (44.9%)  were  between  0 and  2  years.  Among
the  latter,  39/61  (63.9%)  occurred  during  the  ﬁrst  year  of  life  with  highest  incidence  between  4 and  8
months.  A  case-fatality  rate  of 13.2%  was  found,  with  27.8%  cases  below  12  months.  Sepsis  lethality  was
24.4%.  RT-PCR  was  signiﬁcantly  more  sensitive  than  culture:  82  patients  were  tested  at the  same  time
by  both  methods,  either  in  blood  or in  CSF;  MenB  was  found  by  RT-PCR  in  blood  or CSF  in 81/82  cases
(98.8%), culture  identiﬁed  27/82  (32.9%)  infections  (Cohen’s  Kappa  0.3; McNemar’s:  p <  10−5). The  study
shows  that the highest  incidence  of  disease  occurs  in  the  ﬁrst  year  of age,  with  a peak  between  4  and  8
months  of  life;  30% of  deaths  occur  before  12 months.  The  results  suggest  that  the greatest  prevention
could  be obtained  starting  MenB  vaccination  in  the  ﬁrst  months  of life;  a  catch-up  strategy  up  to  the  ﬁfth
year  of  life  could  be  considered.  Our  results  also conﬁrm  that  Realtime  PCR  is signiﬁcantly  more  sensitive
than  culture.  In  those  countries  where  only  isolate  positive  infections  are  counted  as  cases,  the incidence
of MenB  infection  results  highly  underestimated.
 201©. Introduction
Neisseria meningitidis is one of the most frequent causes of
acterial meningitis and septicemia worldwide [1,2]. Meningococ-
al disease is associated with signiﬁcant mortality (10–20%) and
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long-term morbidity [1], especially in pediatric age and 20% of
affected people have permanent neurological disabilities [3–5].
Lethality of sepsis is over 20% in children [6,7]. Prevention is
therefore a priority.
Thirteen different serotypes are known, but, as known, most
invasive meningococcal disease is caused by one of six capsular
groups A, B, C, W135, X and Y. Excellent conjugate vaccines have
been licensed so far. In Italy, since the introduction of conjugate
meningococcal C vaccine (MenC), a rapid and sustained reduction
in the incidence of invasive MenC disease across all age groups
occurred [8,9]. As a consequence, capsular group B (MenB) has
Open access under CC BY-NC-ND license.become responsible for most cases [7,9]. A vaccine against group B
has recently been licensed in Europe and other vaccines are under
study; preliminary data regarding immunogenicity and safety
are promising both in infants and adolescents or adults [10,11].
icense.
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ith the aim to provide broader cross-protection, vaccines under
evelopment include highly conserved subcapsular proteins such
s PorA, variants of factor H binding protein (fHbp), Neisserial Hep-
rin binding Antigen (NHBA) and Neisserial adhesin A (NadA) [1].
n order to plan an effective vaccination schedule, it is important to
now when the greatest burden of meningococcal B disease occurs
nd if vaccine prevention should be done during the ﬁrst year of
ife or later. The aim of the present study is therefore to describe
he epidemiology of invasive meningococcal B disease across
ediatric age groups so to deﬁne the optimal age for vaccination.
. Methods
.1. Study design
This observational, retrospective, cohort study was  designed to
valuate the distribution of meningococcal B invasive disease cases
cross age groups in children admitted with a clinical suspicion of
ommunity-acquired meningitis or sepsis to Pediatric Hospitals or
ediatric wards of general hospitals in Italy from December 2006
o December 2012. This study was a part of a prospective study
imed at obtaining epidemiological and clinical data of Italian chil-
ren with invasive bacterial diseases [12]. Hospitals from all Italian
egions were invited to participate (see Table A, provided as supple-
entary ﬁle, for the characteristic of the participating hospitals).
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.vaccine.
013.09.055.
.2. Case deﬁnition
Bacterial meningitis was suspected in the presence of at least
wo of the following clinical signs: bulging fontanelle, drowsiness
r irritability, opisthotonus, neck stiffness, vomit or seizures [13]
 bacterial meningitis case was deﬁned when clinical signs were
ssociated to the positivity of RT-PCR (Realtime Polymerase Chain
eaction) and/or blood or CSF (Cerebral Spinal Fluid) culture for a
acterium. Meningococcal meningitis was deﬁned by the presence
f clinical suspicion together with chemical CSF tests and the posi-
ivity of culture or RT-PCR on CSF for N. meningitidis. Meningococcal
eningitis was deﬁned associated to sepsis when RT-PCR was pos-
tive for N. meningitidis in blood, too. Sepsis was clinically suspected
n the presence of previously described signs [14,15] and conﬁrmed
y culture or RT-PCR for N. meningitidis.
.3. Patients
All patients aged 0–18 years admitted with a diagnosis of menin-
itis or sepsis to the participating centers during the study period
ere included in the study. Data regarding age, sex, clinical pre-
entation, blood tests, radiologic exams and vaccination status
ere collected. Biological samples were obtained as part of rou-
ine exams for etiologic deﬁnition. The study, partially funded by
he Italian Center for Disease Control (CCM), was approved by the
ocal institutional review board.
.4. Clinical samples
Samples of blood and/or CSF, according to the clinical presen-
ation, were obtained from all children included in the study as
oon as possible after hospital admission and were used for molec-
lar testing by RT-PCR and/or culture. All samples for cultural tests
ere immediately sent to the local laboratory using the proce-
ures established by each hospital for culture tests. All samples for
olecular tests were sent to the central Laboratory (Immunology
aboratory, Anna Meyer Children Hospital, Florence, Italy) using (2014) 1187–1191
a free-post carrier, delivered within the following day and tested
within 2 h after delivery. All the samples for molecular tests were
accompanied by a form collecting demographic and laboratory data
and the main clinical ﬁndings of the patient.
For culture purposes, 4–6 ml  of blood samples (up to 3 sets)
were used. All cases in which RT-PCR or culture demonstrated the
presence of N. meningitidis were serogrouped using molecular tech-
niques; in the central Laboratory 200 l of whole blood were used
for both diagnosis and serogrouping by RT-PCR.
2.5. DNA extraction
Bacterial genomic DNA was  extracted from 200 l of biologi-
cal samples using the QIAmp Dneasy Blood & Tissue kit (Qiagen),
according to the manufacturer’s instructions.
2.6. RT-PCR
RT-PCR ampliﬁcation was  performed in 25 l reaction volumes
containing 2× TaqMan Universal Master Mix  (Applied Biosystem,
Foster City, CA, USA); primers were used at a concentration of
400 nM;  FAM labeled probes at a concentration of 200 nM.  Six l
of DNA extract was used for each reaction. All reactions were per-
formed in triplicate. A negative control (no-template) and a positive
control were included in every run. DNA was  ampliﬁed in an ABI
7500 sequence detection system (Applied Biosystem, Foster City,
CA, USA) using, for all the primers couples, the same cycling param-
eters as follows: 50◦ for 2 min  for UNG digestion 95 ◦C for 10 min
followed by 45 cycles of a two-stage temperature proﬁle of 95 ◦C
for 15 s and 60 ◦C for 1 min. If no increase in ﬂuorescent signal was
observed after 40 cycles, the sample was assumed to be negative.
2.7. Meningococcal serogrouping
All samples which were positive in Realtime-PCR for ctra gene
were included in serogrouping analysis. The following serogroups
were tested: A, B, C, W135, Y using primers and probes as described
in Table 1.
2.8. Statistical analysis
Data was  processed with the SPSSX 11.0 statistical package;
p values < 0.05 were considered statistically signiﬁcant. Results
were expressed as mean levels and standard deviations (SD) or
as median and interquartile range as appropriate. 2 was used to
assess group differences in categorical variables. Odd ratio (OR) and
95% conﬁdence limits (95% CL), when possible, were calculated. For
continuous variables, the t-test was  used with Logarithmic trans-
formation of non-normal distributed variables.
3. Results
3.1. Case distribution according to age
In the study period, 136 cases of invasive meningococcal B dis-
ease were reported. The mean age was  5.0 years, median 2.7 years,
interquartile range 10.2 months–6.4 years.
Among these, 96/136 (70.6%) patients were between 0 and 5
years, 61/136 (45.2%) patients were between 0 and 2 years. Among
cases under 2 years of age, 39/61 (63.9%) occurred during the ﬁrst
year of life. Distribution of cases according to age is shown in Fig. 1.
Within the ﬁrst year of age the highest incidence was observed
between the 4th and the 8th month of age, where 20/39 (51.3%)
cases occurred. Case distribution according to months of age is
shown in Fig. 2.
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Table  1
Primers and probes used for diagnosis and serotyping of meningococcal infection.
Target Gene Forward primer Reverse primer Probe
N. meningitidis ctra gctgcggtaggtggttcaa gctgcggtaggtggttcaa FAM cattgccacgtgtcagctgcacat
Serogroup A sacB cccccagcatggctagattt agggcactttgtggcataattt FAM accctaaaattcaatgggtatatcacga
Serogroup B siaD B ttggacttggttaagctgacctaa gttgacaacatctccattttatcttacc FAM ttagatatgacaaataaattgttacgtggg
Serogroup C siaD C agggaaccgcaacctatgc cacaaaacgttgctcaaattttg FAM ccactcttagaatcatttacatacaaaccc
Serogroup W135/Y siaD W135/Y agggaaccgcaacctatgc cacaaaacgttgctcaaattttg FAM accctaaaattcaatgggtatatcacga
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.2. Culture and RT-PCR sensitivity in blood or CSF
Fifty-two blood samples were tested both by culture and RT-
CR. MenB was found in 43/52 (82.7%); the 9 (17.3%) patients
ho were negative for both tests in blood were positive by
T-PCR in CSF. MenB was identiﬁed by RT-PCR alone in 32/43
74.4%) patients and by both RT-PCR and culture in 11/43 (25.6%)
atients (McNemar’s p < 10−3); no sample was identiﬁed by culture
lone.
Fifty-nine CSF samples were tested both by culture and RT-PCR.
enB was found in 57/59 (96.6%); the 2 (3.4%) patients who were
egative for both tests in CSF were positive by RT-PCR in blood.
enB was identiﬁed by RT-PCR alone in 35/57 (61.4%) patients;
y culture alone in 1/57 (1.8%) and by both RT-PCR and culture in
1/57 (36.8%) patients (McNemar’s p < 10−3).
Overall, 82 patients were tested at the same time by both
olecular and cultural tests either in blood or in CSF or in
oth and a Neisseria meningitidis infection was found by RT-
CR in blood or CSF in 81/82 cases (98.8%). In the same patients
ulture could identify 27/82 (32.9%) infections. RT-PCR was
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ig. 2. Distribution of meningococcal B cases within the ﬁrst 36 months of age.e meningococcal infection (meningitis or sepsis).
signiﬁcantly more sensitive than culture in achieving labora-
tory diagnosis of meningococcal infection (Cohen’s Kappa: 0.3;
McNemar p < 10−5).
Sensitivity according to clinical presentation was  evaluated. In
44 patients who  were admitted to hospital with the diagnosis of
sepsis with or without meningitis, RT-PCR was performed in the
blood of 29/44 and in CSF of 15/44 and was positive in 29/29 (100%)
blood and in 13/15 (86.7%) CSF. Culture was performed in the blood
of 24/44 and in the CSF of 10/44 and was  positive in 6/24 blood
(25.0%) and in 2/10 (20.0%) CSF. As for meningitis, in 90 patients
with the diagnosis of meningitis with no sign of sepsis, RT-PCR was
performed in 39 blood samples and in 61 CSF samples and was  posi-
tive in 29/39 (74.4%) blood samples and 60/61 (98.4%) CSF samples.
Culture was  performed in 31 blood samples and 50 CSF samples
and was  positive in 5/31 (16.1%) blood samples and 21/50 (42.0%)
CSF samples. As expected, CSF is the most suitable sample for diag-
nosis of meningococcal meningitis and blood is the most suitable
sample in meningococcal sepsis. RT-PCR has always a greater sen-
sitivity (2–8 times higher) when compared to culture, ranging from
2.3 times in the CSF of patients with meningitis, to 8.7 times in CSF
of patients with sepsis.
3.3. Case-fatality rate, follow-up and outcome
Over the study period there were 18 deaths, constituting an
overall case fatality ratio (CFR) of 13.2%. Five out of 18 (27.8%)
deaths occurred in the ﬁrst year of age, 9 out of 18 (50.0%) occurred
between the second and the ﬁfth year of age; 3 cases occurred in
adolescents (13–17 years of age). One case occurred at 6.2 years.
CFR was  24.4% (11/45 cases) in children admitted with a diagnosis
of sepsis, and 7.7% (7/91 cases) in children admitted for menin-
gitis and in whom sepsis was not mentioned at admission. Twelve
patients (8.9%) had complications during the acute phase of disease
(cutaneous or subcutaneous necrosis, acute renal failure, seizures).
During the follow-up, severe sequelae such as abnormalities in
Nuclear Magnetic Resonance of brain (gliosis, idrocephalus) asso-
ciated with neurologic symptoms, mental retardation, amputation
of both hand and foot ﬁngers have been reported in 4 patients
(3.0%).
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. Discussion
The results, obtained in a large pediatric population of Italian
atients, demonstrate that invasive meningococcal infection has
he highest incidence in the ﬁrst 5 years of life where over 70%
ases occur and in particular in the ﬁrst year of age, where over
0% of all cases found in pediatric age are found. The incidence
eak, similarly to what reported in other countries [16], is between
he 4th and the 8th month of life.
In parallel with the introduction of routine MenC vaccination in
ifferent Italian regions, the incidence of meningococcal infection
ue to serogroup C has progressively decreased in infants and ado-
escents [8,9,13,17]. However, invasive meningococcal disease is
till the ﬁrst cause of meningitis and is second only to pneumococ-
al infection for cases of sepsis. The most common cause of invasive
eningococcal disease, accounting for over 80% of cases found in
atients younger than 24 years of age [9,17] is now MenB.
Culture has been, so far, the most used technique for
eningococcal surveillance; however, bacterial culture leads to
n important underestimation of disease burden. Conﬁrming
revious results, [16,18,19] once again Realtime PCR results signif-
cantly more sensitive than culture in identifying meningococcal
nfection, independent of the biological sample used and the clini-
al presentation. In fact, in our data obtained in patient tested at the
ame time with both methods, sensitivity of culture was  less than
ne third that of Realtime PCR. This data is particularly important
nd suggests that in those countries (as in Italy) [9] where only
solate positive samples are counted as meningococcal cases, the
ncidence results largely underestimated. Furthermore, it is well
nown that culture-based methods have even lower sensitivity
ompared to molecular methods when the patient has been treated
ith antibiotics [13].
Realtime-PCR has the advantage of providing a diagnosis in the
resence of culture-negative samples [12,13,20,21]; and can also
etermine the capsular group and even the complete sequence
f bacterial genes when needed. Therefore, some countries have
ncluded PCR-based approaches in surveillance procedures, while
erforming cultural tests too. In the United Kingdom, 58% of
aboratory-conﬁrmed meningococcal cases were identiﬁed by PCR
lone [22]; that percentage is even higher in countries with lower
ealth resources, where sample transport and storage negatively
nﬂuence the results; among them Brazil, where the use of PCR has
lmost doubled the ﬁgures obtained by culture tests [19].
RT-PCR has the additional advantage of providing results in less
han 2 h [12] so allowing to start prophylaxis of contacts very soon
nd only when needed.
Case fatality ratio has been recently described to be about 5% for
enB in patients of any age [16]. Our data, obtained in a pediatric
opulation, show a higher fatality rate of 13.2% with almost 30%
ases in the ﬁrst year of age and over 75% in the ﬁrst 5 years of age.
he CFR is even higher for patients presenting with sepsis, where
t reaches 24.4%.
As reported in other western countries [16,23,24] the number
f cases found in our study rapidly increased in the ﬁrst months of
ife, with a peak between the 4th and 8th month of age. Therefore,
n order to obtain the highest effectiveness, the vaccine should be
ffered to all infants in the ﬁrst months of life.
It has been recently demonstrated that the recently licensed
CMenB is highly immunogenic in infants after 3 doses given at
, 3, 4 or 2, 4, 6 months of life [10].
However as demonstrated for other vaccines (either made of
olysaccharides conjugated to proteins or of proteins) in order to
stablish good immune memory and long term protection a dose
n the second year of age is always recommended [25].
It cannot be excluded that a single dose given after the ﬁrst
ear of age could protect also infants through a mechanism of herd (2014) 1187–1191
protection, but this hypothesis has not been demonstrated, so far.
Reduction in carriage is considered an important determinant of the
MenC vaccination success [25] and was  obtained vaccinating at the
same time both infants and adolescent and young adults; classes,
the latter, in which the carriage state is more frequent. The effect
of MenB vaccines on carriage is still under study, but, if undergoing
studies will demonstrate carriage can be eliminated by vaccination,
inclusion of adolescents in vaccination programs would have also
an advantage on protection of infants.
Other approaches for protections of infants in the ﬁrst year of life
could evaluate a cocoon strategy, in which mothers are vaccinated
during pregnancy in order to offer the newborns a passive antibody
protection. No data are available on this procedure which has not
been proven very effective with other vaccines [26] for the presence
of frequent non-household sources of infections.
The present work provided country speciﬁc data which can be
an important key point, as suggested by international recommen-
dations [1] to make sustainable decisions, given the great regional
variability in MenB incidence and serogroup distribution. Since the
available vaccine is made of a mix  of 4 subcapsular protein of MenB,
which can be absent in different MenB isolates, it will be mandatory
to go on with epidemiological studies to evaluate whether, under
the immune pressure induced by vaccination, new mutants which
do not express the 4 proteins target of the vaccine will escape the
immune system [27].
Large epidemiological studies will continue to be needed to
monitor and evaluate the introduction of this new vaccine, and to
measure the impact of vaccination on achieving the goal of elimi-
nating meningococcal disease and RT-PCR should be included in all
surveillance programs in order to obtain more precise evaluation
of incidence, case fatality rate and serogroup distribution.
Acknowledgments
The research was partially supported by the Italian Department
of Health (CCM), by the Anna Meyer Children’s University Hospital
and by the University of Florence.
Conﬂict of interest statement:  The authors have no conﬂict of
interest.
Appendix. Italian group for the study of Invasive Bacterial
Disease
The member of the Italian group are: Agostiniani R, Pistoia;
Allievi P., Garbagnate Milanese; Allù G., Ragusa; Amigoni A.,
Ravenna; Bartolini E., Firenze; Bernardi F., Bologna; Bernardini R.,
Empoli; Biban P., Verona; Bigi M.,  Rimini; Bossi G., Pavia; Bottone U.,
Massa; Cardinale A., Montevarchi; Cardona A., Foligno; Castronari
R., Perugia; Celandroni A., Pontedera; Chiossi M.,  Cuneo; Colleselli
P., Vicenza; Correra A., Napoli; Cortimiglia M., Firenze; D’Ascola G,
Arezzo; De Benedictis F.M., Ancona; de Martino M.,  Firenze; Dini
E., Firenze; Dollfus L., Terni; Domenici R., Lucca; Flacco V., Lan-
ciano; Verrotti A., Perugia; Gaetti MT,  Jesi; Gagliardi L.,Viareggio;
Galli L., Firenze; Giglio P., Gubbio; Guala A., Verbania; Lanari M.,
Imola; Lasagni D., Firenze; Lizzoli C., Magenta; Lombardi E., Firenze;
Magnini M.,  Esine; Mattei R., Lucca; Memmini G., Carrara; Mesirca
P., Montebelluna; Gragnani S., Livorno; Migliozzi L., Senigallia;
Nunziata F., Solofra; Pecile P., Udine; Pepe G., Gallipoli; Perferi
G., Firenze; Peris A., Firenze; Perri P.F., Macerata; Pescollderungg
L., Bolzano; Pezzati M.,  Firenze; Poggi G.M., Firenze; Poggiolesi C.,
Firenze; Rapisardi G., Firenze; Ratta L., Rimini; Ricci S., Firenze; Ridi
F., Firenze; Riva A., Brescia; Rizzo L., Portoferraio; Roman B., Vimer-
cate; Romano F., Firenze; Toffolo A., Oderzo; Strano M.,  Borgo San
Lorenzo; Trapani S., Firenze; Valleriani C., Firenze; Vasarri P., Prato;
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